Improved Xerostomia Prediction in Head and Neck Cancer Patients with Dixon Magnetic Resonance Imaging of Glandular Adiposity: Validation of Semi-Quantitative Parotid T1 Signal Intensity Metrics for Biomarker Pre-Qualification
Authors:
- Keith L. SandersKSKeith L. Sanders
- Sam MulderSMSam Mulder
- Kareem A. WahidKWKareem A. Wahid
- Brigid A. McDonaldBMBrigid A. McDonald
- Sara AhmedSASara Ahmed
- Travis C. SalzilloTSTravis C. Salzillo
- Renjie HeRHRenjie He
- Mohamed A. NaserMNMohamed A. Naser
- Cem DedeCDCem Dede
- Vivian SalamaVSVivian Salama
- Ashley WayAWAshley Way
- Christina Setareh SharafiCSChristina Setareh Sharafi
Preprint
Abstract
Purpose: Parotid whole-gland magnetic resonance (MR) T1 intensity, thresholded at the 90th percentile (T1 P90), has been previously reported to be a candidate MR imaging biomarker (MR-IBM) for improved prediction of xerostomia development after radiotherapy. Although P90 was previously derived from the parotid glands of T1-weighted MRI, in this study, we aim to validate P90 in an external cohort using fat only images reconstructed from a T1 Dixon MRI sequence, as well as determining alternative T1 intensity thresholds for potential qualification as predictive FDA BEST biomarkers of xerostomia development 6 months after radiotherapy (Xero 6m ). Methods: MR-IBMs derived from T1 Dixon intensity-normalized scans from 76 head and neck cancer (HNC) patients were extracted from pre-treatment MR images. Scans were normalized to fat tissue, and imaging characteristics were quantified. A reference model and MR-IBM models were created using multivariable logistic regression to predict Xero 6m . External validation was performed using the model coefficients described in a previous study. The area under the curve (AUC) of the resulting models were compared. Stepwise forward feature selection was performed to discover additional MR-IBMs for improved predictions of xerostomia. Results: The external validation of a previous model coefficients against our cohort showed decreased performance of the P90 MR-IBM model (AUC of 0.73 (CI 0.61-0.85)). The reference model exhibited improved performance when P90 was incorporated (AUC of 0.78 (CI 0.67-0.89)). Feature selection demonstrated the P10 MR-IBM provided performance improvements (AUC of 0.79 (CI: 0.69-0.90)). Conclusion: Our findings validated P90 as predictive biomarker for radiation-induced xerostomia and showed MR-IBMs derived from Dixon sequences can improve Xero 6m prediction when compared to the reference model. Formal biomarker qualification should be considered for T1 sequences/relaxometry via formalized approaches.Keywords
This publication has 24 references indexed in Scilit:
- Dixon-based Magnetic Resonance Imaging for Early Prediction of Patient-Reported Acute Xerostomia following Head and Neck RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- Role of chemical shift and Dixon based techniques in musculoskeletal MR imagingEuropean Journal of Radiology, 2017
- Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophyJournal of Neurology, 2017
- Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approachRadiotherapy and Oncology, 2013
- Protons in Head-and-Neck Cancer: Bridging the Gap of EvidenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: The role of dosimetric and clinical factorsRadiotherapy and Oncology, 2012
- Dixon techniques for water and fat imagingJournal of Magnetic Resonance Imaging, 2008
- MRI/linac integrationRadiotherapy and Oncology, 2008
- Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck moduleHead & Neck, 2007
- Intensity modulated photon and proton therapy for the treatment of head and neck tumorsRadiotherapy and Oncology, 2006